

proposed rule. Therefore, we are extending the comment period until October 23, 2015.

Dated: September 23, 2015.

Robert G. McSwain,

Deputy Director, Indian Health Service.

[FR Doc. 2015-25211 Filed 10-2-15; 8:45 am]

BILLING CODE 4165-16-P

DEPARTMENT OF HEALTH AND HUMAN SERVICES

National Institutes of Health

National Center for Advancing Translational Sciences: Notice of Closed Meeting

Pursuant to section 10(d) of the Federal Advisory Committee Act, as amended (5 U.S.C. App.), notice is hereby given of the following meeting.

The meeting will be closed to the public in accordance with the provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5 U.S.C., as amended. The grant applications and the discussions could disclose confidential trade secrets or commercial property such as patentable material, and personal information concerning individuals associated with the grant applications, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy.

Name of Committee: National Center for Advancing Translational Sciences Special Emphasis Panel; NIH SUPPORT FOR CONFERENCE AND SCIENTIFIC MEETINGS.

Date: October 22–23, 2015.

Time: 8 a.m. to 5 p.m.

Agenda: To review and evaluate grant applications.

Place: National Institutes of Health, One Democracy Plaza, 6701 Democracy Boulevard, Bethesda, MD 20892 (Virtual Meeting).

Contact Person: M. Lourdes Ponce, Scientific Review Officer, Office of Scientific Review, National Center For Advancing Translational Sciences (NCATS), National Institutes of Health, 6701 Democracy Blvd., Democracy 1, Room 1073 Bethesda, MD 20892, 301-594-9459, poncel@mail.nih.gov. (Catalogue of Federal Domestic Assistance Program Nos. 93.859, Pharmacology, Physiology, and Biological Chemistry Research; 93.350, B—Cooperative Agreements; 93.859, Biomedical Research and Research Training, National Institutes of Health, HHS)

Dated: September 29, 2015.

David Clary,

Program Analyst, Office of Federal Advisory Committee Policy.

[FR Doc. 2015-25198 Filed 10-2-15; 8:45 am]

BILLING CODE 4140-01-P

DEPARTMENT OF HEALTH AND HUMAN SERVICES

National Institutes of Health

National Institute of Dental & Craniofacial Research; Notice of Closed Meetings

Pursuant to section 10(d) of the Federal Advisory Committee Act, as amended (5 U.S.C. App.), notice is hereby given of the following meetings.

The meetings will be closed to the public in accordance with the provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5 U.S.C., as amended. The grant applications and the discussions could disclose confidential trade secrets or commercial property such as patentable material, and personal information concerning individuals associated with the grant applications, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy.

Name of Committee: National Institute of Dental and Craniofacial Research Special Emphasis Panel; Review of DSR Member Conflict & R13 Applications.

Date: October 28, 2015.

Time: 10:00 a.m. to 12:30 p.m.

Agenda: To review and evaluate grant applications.

Place: National Institutes of Health, One Democracy Plaza, 6701 Democracy Boulevard, Bethesda, MD 20892.

Contact Person: Victor Henriquez, Ph.D., Scientific Review Officer DEA/SRB/NIDCR, 6701 Democracy Blvd., Room 668, Bethesda, MD 20892-4878, 301-451-2405, henriquv@nidcr.nih.gov.

Name of Committee: National Institute of Dental and Craniofacial Research Special Emphasis Panel; NIDCR Oral HIV Reservoirs SEP.

Date: November 5–6, 2015.

Time: 8:00 a.m. to 12:00 p.m.

Agenda: To review and evaluate grant applications.

Place: Hyatt Regency Bethesda, One Bethesda Metro Center, 7400 Wisconsin Avenue, Bethesda, MD 20814.

Contact Person: Crina Frincu, Ph.D., Scientific Review Officer Scientific Review Branch, National Institute of Dental and Craniofacial Research, National Institutes of Health 6701 Democracy Blvd., Suite 662, Bethesda, MD 20892 cfrincu@mail.nih.gov. (Catalogue of Federal Domestic Assistance Program Nos. 93.121, Oral Diseases and Disorders Research, National Institutes of Health, HHS)

Dated: September 30, 2015.

David Clary,

Program Analyst, Office of Federal Advisory Committee Policy.

[FR Doc. 2015-25265 Filed 10-2-15; 8:45 am]

BILLING CODE 4140-01-P

DEPARTMENT OF HEALTH AND HUMAN SERVICES

National Institutes of Health

Center for Scientific Review; Amended Notice of Meeting

Notice is hereby given of a change in the meeting of the Center for Scientific Review Special Emphasis Panel, October 9, 2015, 8:30 a.m. to October 9, 2015, 7:00 p.m., The Dupont Circle Hotel, 1500 New Hampshire Avenue NW., Washington, DC, 20036 which was published in the **Federal Register** on September 16, 2015, 80 FR 55635.

The meeting title was changed to: “Nursing and Related Clinical Sciences Overflow Meeting”. All other details remain unchanged. The meeting is closed to the public.

Dated: September 30, 2015.

David Clary,

Program Analyst, Office of Federal Advisory Committee Policy

[FR Doc. 2015-25263 Filed 10-2-15; 8:45 am]

BILLING CODE 4140-01-P

DEPARTMENT OF HEALTH AND HUMAN SERVICES

National Institutes of Health

Government-Owned Invention; Availability for Licensing

AGENCY: National Institutes of Health, HHS.

ACTION: Notice.

SUMMARY: The invention listed below is owned by an agency of the U.S. Government and are available for licensing in the U.S. in accordance with 35 U.S.C. 209 and 37 CFR part 404 to achieve expeditious commercialization of results of federally-funded research and development. Foreign patent applications are filed on selected inventions to extend market coverage for companies and may also be available for licensing.

FOR FURTHER INFORMATION CONTACT: Licensing information and copies of the U.S. patent applications listed below may be obtained by contacting Jasmine Yang, Ph.D., at the Technology Advancement Office, National Institute of Diabetes and Digestive and Kidney Diseases, Building 12A, Suite 3011 (MSC 5632), Bethesda MD 20892; Telephone: 301-451-7836; Email: jasmine.yang@nih.gov. A signed Confidential Disclosure Agreement will be required to receive copies of the patent applications.

SUPPLEMENTARY INFORMATION: Technology description follows.

Cannabinoid Receptor 1 (CB1) Inverse Agonists for the Treatment of Diabetes, Obesity and Their Complications

Description of Technology: Cannabinoid (CB1 and CB2) receptors recognize and mediate the effects of the active compound tetrahydrocannabinol found in marijuana. CB1 receptor activation plays a key role in appetitive behavior and metabolism.

Dr. Kunos and colleagues have designed a set of CB1 receptor inverse agonists that are effective at reducing obesity and its associated metabolic consequences while not causing the adverse neuropsychotropic side effects linked to earlier antagonists such as rimonabant. The CB1 receptor compounds were developed with the goals of (1) limiting their brain penetrance without losing their metabolic efficacy due to CB1 inverse agonism, and (2) generating compounds whose primary metabolite directly targets enzymes involved in inflammatory and fibrotic processes associated with metabolic disorders. The patent application of this technology are to the composition of matter and methods of use to the cannabinoid receptor (CB1) blocking compounds for the treatment of obesity, diabetes, fatty liver disease and a variety of obesity-related metabolic syndromes. The technology has the potential to be the next generation of safer CB1 receptor therapeutics for treating obesity.

Potential Commercial Applications:

- Treatment for obesity
- Treatment for metabolic syndrome
- Treatment of diabetes
- Treatment of fibrosis
- Treatment of Fatty Liver Disease such as Nonalcoholic steatohepatitis (NASH)

Competitive Advantages:

- Inhibits metabolic activity without causing psychiatric side effects
- Offers improved anti-inflammatory and anti-fibrotic efficacy

Development Stage:

- In vitro data available

- In vivo data available (animal)

Inventors: George Kunos (NIAAA), Malliga Iyer (NIAAA), Resat Cinar (NIAAA), Kenner Rice (NIDA)

Intellectual Property:

- HHS Reference No. E-282-2012/0-US-01—US Provisional Patent Application No. 61/725,949 filed November 13, 2012
- HHS Reference No. E-282-2012/0-PCT-02—PCT Application No. PCT/US2013/069686 filed November 12, 2013
- HHS Reference No. E-282-2012/0-US-03—US Patent Application No. 14/442,383 filed May 12, 2015

- HHS Reference No. E-282-2012/0-CA-04—Canadian Patent Application No. 2889697 filed April 27, 2015
 - HHS Reference No. E-282-2012/0-EP-05—European Patent Application No. 13802153.0 filed June 01, 2015
 - HHS Reference No. E-282-2012/0-IN-06—Indian Patent Application No. 3733/DELNP/2015 filed May 01, 2015
 - HHS Reference No. E-282-2012/0-JP-07—Japanese Patent Application No. 2015-542015 filed May 11, 2015
 - HHS Reference No. E-282-2012/0-CN-08—Chinese Patent Application No. 201380069389.9 filed July 3, 2015
 - HHS Reference No. E-282-2012/1-US-01—US Provisional Application No. 62/171,179 filed June 04, 2015
- Licensing Contact: Jasmine Yang, Ph.D.; 301-451-7836; jasmine.yang@nih.gov

Collaborative Research Opportunity: The National Institute on Alcohol Abuse and Alcoholism, Laboratory of Physiologic Studies, is seeking statements of capability or interest from parties interested in collaborative research to further develop, evaluate or commercialize peripherally restricted CB1 receptor blockers with improved efficacy. For collaboration opportunities, please contact George Kunos, M.D., Ph.D. at George.Kunos@nih.gov or 301-443-2069.

Dated: September 29, 2015.

Richard U. Rodriguez,

Acting Director, Office of Technology Transfer, National Institutes of Health.

[FR Doc. 2015-25197 Filed 10-2-15; 8:45 am]

BILLING CODE 4140-01-P

DEPARTMENT OF HEALTH AND HUMAN SERVICES

National Institutes of Health

National Heart, Lung, and Blood Institute; Notice of Meeting

Pursuant to section 10(a) of the Federal Advisory Committee Act, as amended (5 U.S.C. App.), notice is hereby given of a meeting of the Sleep Disorders Research Advisory Board.

The meeting will be open to the public and conducted electronically. The public is encouraged to observe the meeting, and should request instructions from the Contact Person listed below in advance.

Name of Committee: Sleep Disorders Research Advisory Board.

Date: October 9, 2015.

Time: 1:00 p.m. to 3:00 p.m.

Agenda: To discuss plans for the proposed revision of the NIH Sleep Disorders Research Plan, and potential directions for inter-agency coordination activities.

Place: National Institutes of Health, 6701 Rockledge Drive, Bethesda, MD 20892 (Virtual Meeting).

Contact Person: Michael J. Twery, Ph.D., Director, National Center on Sleep Disorders Research, Division of Lung Diseases, National Heart, Lung, and Blood Institute, National Institutes of Health, 6701 Rockledge Drive, Suite 10038, Bethesda, MD 20892-7952, 301-435-0199 twerym@nhlbi.nih.gov.

This notice is being published less than 15 days prior to the meeting due to internal discussions regarding agenda and scheduling details.

Information is also available on the Institute's/Center's home page: <http://www.nhlbi.nih.gov/about/committees>, where an agenda and any additional information for the meeting will be posted when available.

(Catalogue of Federal Domestic Assistance Program Nos. 93.233, National Center for Sleep Disorders Research; 93.837, Heart and Vascular Diseases Research; 93.838, Lung Diseases Research; 93.839, Blood Diseases and Resources Research, National Institutes of Health, HHS)

Dated: September 30, 2015.

Michelle Trout,

Program Analyst, Office of Federal Advisory Committee Policy.

[FR Doc. 2015-25266 Filed 10-2-15; 8:45 am]

BILLING CODE 4140-01-P

DEPARTMENT OF HEALTH AND HUMAN SERVICES

National Institutes of Health

Center for Scientific Review; Notice of Closed Meetings

Pursuant to section 10(d) of the Federal Advisory Committee Act, as amended (5 U.S.C. App.), notice is hereby given of the following meetings.

The meetings will be closed to the public in accordance with the provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5 U.S.C., as amended. The grant applications and the discussions could disclose confidential trade secrets or commercial property such as patentable material, and personal information concerning individuals associated with the grant applications, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy.

Name of Committee: Center for Scientific Review Special Emphasis Panel; Member Conflict: Cognition and Memory.

Date: October 30, 2015.

Time: 2:00 p.m. to 4:00 p.m.

Agenda: To review and evaluate grant applications.

Place: National Institutes of Health, 6701 Rockledge Drive, Bethesda, MD 20892 (Virtual Meeting).

Contact Person: Wind Cowles, Ph.D., Scientific Review Officer, Center for Scientific Review, National Institutes of